immuno-oncology

Nurix Therapeutics unveils preclinical data showing protein degradation pipeline effectiveness, with NRX-0305 achieving 142% lifespan extension in melanoma models.

Boehringer Ingelheim and Zai Lab collaborate on Phase Ib/II study combining T-cell engager obrixtamig with ADC zocilurtatug for small cell lung cancer treatment.

Oxford BioTherapeutics partners with Bristol Myers Squibb to develop T-cell engager therapies for solid tumors, marking third major pharma deal in a year.

Xilio Therapeutics granted stock options for 3,257 shares to two new employees at $8.48 exercise price, reflecting typical equity compensation practices for biotech hiring.

Over 50 companies compete in the checkpoint inhibitor market with 60+ drug candidates in development. Major consolidation and innovation drive immuno-oncology growth through 2026.

Liminatus Pharma prices $4M share offering to fund immuno-oncology pipeline development, specifically advancing CD47-blockade therapeutic programs.